Author(s): Spyridon E. Kintzios (Editor); Maria G. Barberaki (Editor)
Publisher: CRC Press, Year: 2019
Divided into four segments, the first part is dedicated to a review of our current knowledge of cancer, the different types and incidence, the molecular pathways of the disease, and the various treatment protocols, with an emphasis on chemotherapy. The second part is a brief journey in pharmacognosy, with detailed information about each of the fourteen different chemical groups of plant secondary metabolites, their use in cancer chemotherapy, and updated information on the biotechnological production of the most representative compounds in clinical practice. The third part of the book comprises six chapters dedicated to either plant chemotherapeutical approaches to specific cancer types (e.g. bladder, prostate) or specific groups of plant secondary metabolites with novel and promising properties for cancer treatment (e.g. naphthoquinones, lectins, phenanthridone alkaloids). The fourth part, containing investigative information on almost 300 individual plant species with established anticancer properties, either on a clinical or in vitro level, is with no doubt the most analytical.
This new edition contains chapters on cytotoxic phenanthridone alkaloid constituents of the Amaryllidaceae; naphthoquinone-contained anticancer terrestrial plants; polyphenols and cancer immunology; medicinal plant product-based fabrication nanoparticles (Au and Ag) and their anticancer effects; bladder and prostate cancer; and plant lectins in cancer treatment.
• Provides efficient information for all kinds of cancer and plant chemotherapeutical approaches to specific cancer types
• Discusses specific groups of plant secondary metabolites with novel and promising properties for cancer treatment
• Provides scientific information for medicinal uses of various plants
• Contains analytical information on almost 300 individual plant species with established anticancer properties, either on a clinical or in vitro level
• Focuses on plant genera and species that are either already used in cancer chemotherapy or have been identified with antitumor and antileukemic properties to a bigger or lesser extent